ArticleMetabolomics : Official journal of the Metabolomic Society2026
Metabolic markers of kidney function and oxidative stress are associated with heart failure with preserved ejection fraction (HFpEF) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMetabolic dysfunction-associated steatotic liver disease (MASLD) is associated with heart failure with preserved ejection fraction (HFpEF), independent of shared risk factors. The aim of this study was to discover metabolic pathways associated with HFpEF in individuals with MASLD to explore shared mechanisms and identify biomarkers of risk.
methodsWe examined HFpEF cases and non-HF controls in the Duke CATHeterization GENetics (CATHGEN) study. HFpEF was defined as left ventricular ejection fraction (LVEF) ≥ 45%, diastolic dysfunction grade ≥ 1 on transthoracic echocardiogram (TTE), and history of clinical heart failure. MASLD was phenotyped using ICD codes or hepatic steatosis index (HSI) > 36, in the presence of ≥ 1 metabolic risk factor. Metabolomic profiling was performed in fasting plasma using targeted tandem flow injection (absolute quantification, n = 60) and non-targeted (relative quantification, n = 210) mass spectrometry. Logistic regression models tested the association between metabolite factors and HFpEF. An interaction term analyzed the influence of MASLD on associations between metabolites and HFpEF.
resultsA total of 430 participants were included; 247 (57.4%) had HFpEF. In participants with MASLD (N = 222, 51.6%), a factor composed of markers of kidney function, acylcarnitines, and modified amino acids was associated with HFpEF (OR: 2.2, 95% CI: 1.5-3.2, FDR-adjusted p-value = 0.002). The association of a PC composed primarily of ketoglutarate and phenyl sulfate with HFpEF was modified by MASLD (unadjusted p-value = 0.03).
conclusionsMarkers of kidney function and mitochondrial metabolism were associated with HFpEF in participants with MASLD. Mitochondrial energy pathways may link MASLD to HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.